• 1
    Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007; 94: 274-286.
  • 2
    Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol. 2008; 34: 609-614.
  • 3
    Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin on resectability of hepatic colorectal metastases, J Am Coll Surg. 2005; 200: 845-853.
  • 4
    Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24: 2065-2072.
  • 5
    Gilat T, Somjen GJ, Mazur Y, et al. Fatty acid bile acid conjugates (FABACs)—new molecules for the prevention of cholesterol crystallisation in bile. Gut. 2001; 48: 75-79.
  • 6
    Gilat T, Leikin-Frenkel A, Goldiner I, et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology. 2003; 38: 436-442.
  • 7
    Gilat T, Leikin-Frenkel A, Goldiner I, et al. Reduction of established fat induced fatty liver in rodents by oral Fatty Acid Bile Acid Conjugates (FABACs) [abstract]. Presented at 14th United European Gastroenterology Week; Berlin, Germany; October 21-25, 2006.
  • 8
    Konikoff FM, Leikin-Frenkel A, Gilat T. Fatty acid bile acid conjugates—novel agents for the prevention and treatment of gallstones. In: AlderG, ed. Gallstones: Pathogenesis and Treatment. Lancaster, United Kingdom: Kluwer Academic Publishers; 2004: 157-161.
  • 9
    Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957; 226: 497-509.
  • 10
    Leikin AI, Brenner RR. Lipid-binding properties of a factor necessary for linoleic acid desaturation. Lipids. 1979; 14: 1021-1026.
  • 11
    Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol. 1991; 28: 192-198.
  • 12
    Louvet C, Coudray AM, Tournigand C, et al. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs. 2000; 11: 579-582.
  • 13
    Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys. 2002; 52: 1092-1098.
  • 14
    Boughattas NA, Hecquet B, Fournier C, et al. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos. 1994; 15: 761-773.
  • 15
    Tortora G, Ciardiello F, Damiano V, et al. Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Ann Oncol. 2002; 13: 392-398.
  • 16
    Leikin-Frenkel A, Bonen H, Tirosh O, et al. Fatty acid bile acid conjugates reduce de novo fatty acid synthesis, SCD1 activity and stimulate β-oxidation in hepatocytes (abstracts from the49th International Conference on the Bioscience of Lipids) [abstract]. Chem Phys Lipids. 2008; 154( suppl 1): S48.
  • 17
    Konikoff FM, Leikin-Frenkel A, Goldiner I, et al. Biliary and systemic effects of fatty acid bile acid conjugates (FABACs). Eur J Gastroenterol Hepatol. 2003; 15: 1-8.